Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2012; 18(45): 6560-6570
Published online Dec 7, 2012. doi: 10.3748/wjg.v18.i45.6560
Published online Dec 7, 2012. doi: 10.3748/wjg.v18.i45.6560
Ref. | Specimen | CCKBR expression | G17 expression | G17 effects |
Haigh et al[4] | Esophageal biopsies from healthy, esophagitis, BE and EAC patients; Ex vivo culture of BE cells; OE33(E)GR cells | CCKBR is expressed in 3/9 of healthy, 5/7 esophagitis, 10/10 BE and 7/12 EAC samples | Not assessed | G17 stimulates cell proliferation through CCKBR |
Konturek et al[46] | Tumor and plasma samples from CRC patients; Plasma and normal colonic mucosa biopsies from healthy subjects | All the tumor samples showed CCKBR expression | CRC patients showed normal G17 plasma levels, and higher progastrin levels than healthy subjects; Celecoxib diminished plasma gastrin and progastrin levels | Not assessed |
Smith et al[49] | Healthy colonic mucosa and colonic polyps biopsies | Normal colonic mucosa didn’t show CCKBR expression; Most of the polyps analyzed showed CCKBR expression | Most of the polyps showed higher expression of the gastrin precursors than amidated forms | Not assessed |
Harris et al[70] | Healthy esophagus and BE biopsies; OE19 and OE33 cell culture; OE21 cell culture | All three esophageal cancer cell lines express CCKBR; BE biopsies show higher CCKBR expression levels than normal esophageal biopsies | BE samples express higher gastrin levels than healthy esophageal biopsies | G17 increases activation of the antiapoptotic factor PKB/Akt, through CCKBR |
Ref. | Animal model | Alteration on gastrin peptides levels | Hypergastrinemia effects |
Cobb et al[2] | Fabp-wt mice; Fabp-mt mice | Fabp-wt mice express human PG in intestinal mucosa and Fabp-mt mice express a mutated form of human PG; Both mice show PG expression at similar levels as seen in hypergastrinemia | Mice overexpressing human PG (either the wild-type and the mutated form) are more likely to develop colonic tumors in response to AOM |
Wang et al[5] | INS-GAS mice; hGAS mice | INS-GAS mice overexpress human amidated gastrin in the pancreatic islands; hGAS mice overexpress human PG in the liver | Both forms of gastrin showed similar proliferative effects on normal colonic mucosa |
Havu et al[34] | Sprague-Dawley rats treated with ranitidine (2g/kg per day) | Rats showed a 3-fold increase in plasma gastrin levels | 19/100 rats developed ECL carcinoids while no carcinoma was found in control animals |
Watson et al[43] | APCMin+/- mice (model of multiple intestinal neoplasia) treated with omeprazole (75 mg/kg in a single oral dose) | Omeprazole increased only amidated gastrin plasma levels | PPI-induced hypergastrinemia reduced mice survival; Hypergastrinemia increased colonic adenomas proliferation; Hypergastrinemia did not increase the incidence of intestinal tumors |
Ferrand et al[90] | MTI/G-Gly mice; hGAS mice | MTI/G-Gly mice overexpress human G-Gly throughout the gastrointestinal tract; hGAS mice overexpress human PG in the liver | Both G-Gly and PG strongly up-regulate Src, JAK2 and STAT3 activation; PG produced significantly great ERK and Akt pathways activation and TGF-α overexpression |
Koh et al[95] | MTI/G-Gly mice | MTI/G-Gly mice overexpress human G-Gly throughout the gastrointestinal tract | Goblet cells hyperplasia and colonic hyperproliferation; Hypergastrinemia did not increase the incidence of GI tumors, but 3/10 mice developed bronchoalveolar carcinoma |
Ottewell et al[98] | G-/-hg+/+ mice; G-/-hg-/- mice | G-/-hg+/+ mice express human PG and no murine gastrin; G-/-hg-/- mice do not express any forms of gastrin | PG increased colonic proliferation; PG exerts mitotic effects on colonic epithelia but does not seem to affect the small intestine epithelia |
Ref. | Population studied | Treatment, dose and duration | Effects on gastrin levels | Physiopathological effects |
Brunner et al[35] | 143 patients with duodenal or stomach ulcer and GERD | Omeprazole 40 mg/d 1-5 yr | Plasma gastrin levels increased 4-fold after 4 mo of therapy | Hyperplasia of argyrophil cells from oxyntic mucosa; No increase in dysplasia or neoplasia rates was observed |
Klinkenberg-Knol et al[37] | 91 GERD patients | Omeprazole 20-40 mg/d 5 yr | Median serum gastrin levels increased from 60 to 162 ng/L and reached a plateau during maintenance treatment | Esophagitis symptoms ameliorated; Gastric hyperplasia rates increased from 2.5% at the beginning of the study to 20% at last biopsy |
Nemeth et al[39] | 10 patients with oesophagitis | Omeprazole 20 mg/d 6-8 wk | Plasma levels of amidated gastrins increased from 18 to 48 pmol/L; Antral levels of progastrin increased 6-fold while amidated gastrins and G-Gly remain unaltered | Not assessed |
Wang et al[42] | 82 BE patients; 13 GERD patients | All patients were on PPI therapy, once or twice daily during a median time of 74 mo | The median serum gastrin levels (40 pmol/L) was not related to the degree of dysplasia in BE | Higher serum gastrin levels were associated with high grade dysplasia and adenocarcinoma |
Creutzfeldt et al[53] | 74 patients with esophagitis or peptic ulcer | Omeprazole 40 mg/d 1-5 yr | Plasma gastrin levels increased 4-fold in 23% of patients | Patients with higher serum gastrin levels developed hyperplasia of the gastric argyrophil cells; This hyperplasia may not necessary be related to high gastrin levels |
Kuipers et al[54] | 177 GERD patients | 105 patients treated with omeprazole 20-40 mg/d 5 yr; 72 patients treated with fundoplication | Not assessed | Patients treated with omeprazole and infected with H.pylori infection are at increased risk of atrophic gastritis |
Lamberts et al[55] | 74 peptic ulcer patients | Omeprazole 48 mo | Median gastrin levels moderately increased after 3 mo of therapy and reached a plateau during maintenance treatment | Significant argyrophil cell hyperplasia |
- Citation: Chueca E, Lanas A, Piazuelo E. Role of gastrin-peptides in Barrett's and colorectal carcinogenesis. World J Gastroenterol 2012; 18(45): 6560-6570
- URL: https://www.wjgnet.com/1007-9327/full/v18/i45/6560.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i45.6560